{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:55Z","timestamp":1790707255604,"version":"4.1.0"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,10,14]]},"DOI":"10.18632\/oncotarget.28278","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T12:42:48Z","timestamp":1665751368000},"page":"1122-1135","source":"Crossref","is-referenced-by-count":19,"title":["HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: Implications for their use in combination with PARP inhibitors and chemotherapeutic drugs"],"prefix":"10.18632","volume":"13","author":[{"given":"Benigno C.","family":"Valdez","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje S.","family":"Andersson","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H","article-title":"Roles of histone acetyltransferases and deacetylases in gene regulation","volume":"2","author":"Allis","year":"1998","journal-title":"Bioessays"},{"key":"2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X","article-title":"Histone acetylation and an epigenetic code","volume":"2","author":"Turner","year":"2000","journal-title":"Bioessays"},{"key":"3","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"2","author":"Seto","year":"2007","journal-title":"Oncogene"},{"key":"4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/1947601911417176","article-title":"Histone modifiers in cancer: friends or foes?","volume":"2","author":"Schneider","year":"2011","journal-title":"Genes Cancer"},{"key":"5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","article-title":"HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases","volume":"5","author":"Eom","year":"2016","journal-title":"Chonnam Med J"},{"key":"6","first-page":"166","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Bae","year":"2011","journal-title":"Am J Transl Res"},{"key":"7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/leu.2014.244","article-title":"Novel drugs for older patients with acute myeloid leukemia","volume":"2","author":"Garcia-Manero","year":"2015","journal-title":"Leukemia"},{"key":"8","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/cncr.30100","article-title":"Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma","volume":"12","author":"Anderlini","year":"2016","journal-title":"Cancer"},{"key":"9","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/cancers11111794","article-title":"HDAC Inhibitors in Acute Myeloid Leukemia","volume":"1","author":"Prosper","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10","doi-asserted-by":"publisher","first-page":"63829","DOI":"10.18632\/oncotarget.11561","article-title":"Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy","volume":"7","author":"Andersson","year":"2016","journal-title":"Oncotarget"},{"key":"11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"4","author":"Garc\u00eda-Sancho","year":"2022","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nature01368","article-title":"DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation","volume":"42","author":"Kastan","year":"2003","journal-title":"Nature"},{"key":"13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nsmb.2499","article-title":"Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination","volume":"2","author":"Greenberg","year":"2013","journal-title":"Nat Struct Mol Biol"},{"key":"14","doi-asserted-by":"publisher","first-page":"10406","DOI":"10.3390\/ijms221910406","article-title":"Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy","volume":"2","author":"Terpos","year":"2021","journal-title":"Int J Mol Sci"},{"key":"15","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.18632\/oncotarget.2154","article-title":"Histone deacetylase inhibitor treatment induces \u2018BRCAness\u2019 and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells","volume":"5","author":"Bhalla","year":"2014","journal-title":"Oncotarget"},{"key":"16","doi-asserted-by":"publisher","first-page":"978371","DOI":"10.1155\/2015\/978371","article-title":"Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line","volume":"201","author":"Damante","year":"2015","journal-title":"Int J Endocrinol"},{"key":"17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13058-015-0534-y","article-title":"Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells","volume":"1","author":"Bang","year":"2015","journal-title":"Breast Cancer Res"},{"key":"18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.molonc.2015.12.014","article-title":"Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma","volume":"1","author":"Hamerlik","year":"2016","journal-title":"Mol Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13046-022-02290-9","article-title":"Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/. BRCA1 DNA damage repair complex in prostate cancer cells","volume":"4","author":"Li","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41589-018-0097-1","article-title":"Acetylation blocks DNA damage-induced chromatin ADP-ribosylation","volume":"1","author":"Muir","year":"2018","journal-title":"Nat Chem Biol"},{"key":"21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4161\/cc.4.4.1564","article-title":"Histone deacetylase inhibitors in programmed cell death and cancer therapy","volume":"4","author":"Jiang","year":"2005","journal-title":"Cell Cycle"},{"key":"22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/(sici)1097-4644(199701)64:1<50::aid-jcb8>3.0.co;2-z","article-title":"Macromolecular substrates for the ICE-like proteases during apoptosis","volume":"6","author":"Casciola-Rosen","year":"1997","journal-title":"J Cell Biochem"},{"key":"23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bcp.12761","article-title":"Olaparib","volume":"8","author":"Rissmann","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"1","author":"Szabo","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"25","doi-asserted-by":"publisher","first-page":"723847","DOI":"10.3389\/fgene.2021.723847","article-title":"Homologous Recombination Subpathways: A Tangle to Resolve","volume":"1","author":"L\u00f6brich","year":"2021","journal-title":"Front Genet"},{"key":"26","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.jmb.2015.11.021","article-title":"Patching Broken DNA: Nucleosome Dynamics and the Repair of DNA Breaks","volume":"42","author":"Price","year":"2016","journal-title":"J Mol Biol"},{"key":"27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1083\/jcb.201001048","article-title":"The NuRD chromatin-remodeling complex regulates signaling and repair of DNA damage","volume":"19","author":"van Attikum","year":"2010","journal-title":"J Cell Biol"},{"key":"28","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1182\/bloodadvances.2020002049","article-title":"The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1","volume":"4","author":"Akilov","year":"2020","journal-title":"Blood Adv"},{"key":"29","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.exphem.2012.06.001","article-title":"Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines","volume":"4","author":"Andersson","year":"2012","journal-title":"Exp Hematol"},{"key":"30","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.bbmt.2018.02.020","article-title":"Phase II Trial of High-Dose Gemcitabine\/Busulfan\/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma","volume":"2","author":"Alousi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrm3376","article-title":"New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs","volume":"1","author":"Kraus","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"32","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.bbmt.2015.06.003","article-title":"Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas","volume":"2","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.dnarep.2014.03.021","article-title":"Protein ADP-ribosylation and the cellular response to DNA strand breaks","volume":"1","author":"Caldecott","year":"2014","journal-title":"DNA Repair (Amst)"},{"key":"34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00412-013-0442-9","article-title":"Poly(ADP-ribosyl)ation in regulation of chromatin structure and the DNA damage response","volume":"12","author":"Ahel","year":"2014","journal-title":"Chromosoma"},{"key":"35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/CMAR.S346052","article-title":"Targeted Cancer Therapy Based on Acetylation and Deacetylation of Key Proteins Involved in Double-Strand Break Repair","volume":"1","author":"Zhao","year":"2022","journal-title":"Cancer Manag Res"},{"key":"36","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1158\/1541-7786.MCR-20-0833","article-title":"R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin","volume":"1","author":"Bates","year":"2021","journal-title":"Mol Cancer Res"},{"key":"37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ygyno.2021.04.015","article-title":"Entinostat, a selective HDAC1\/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer","volume":"16","author":"Cybulla","year":"2021","journal-title":"Gynecol Oncol"},{"key":"38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neo.2021.12.002","article-title":"Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer","volume":"2","author":"Khabele","year":"2022","journal-title":"Neoplasia"},{"key":"39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.leukres.2016.03.007","article-title":"Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin","volume":"4","author":"Rassool","year":"2016","journal-title":"Leuk Res"},{"key":"40","doi-asserted-by":"publisher","first-page":"745922","DOI":"10.3389\/fcell.2021.745922","article-title":"The Making and Breaking of Serine-ADP-Ribosylation in the DNA Damage Response","volume":"9","author":"Ahel","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bcp.2012.03.018","article-title":"The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art","volume":"8","author":"Dantzer","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"42","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.leukres.2008.01.016","article-title":"Altered gene expression in busulfan-resistant human myeloid leukemia","volume":"3","author":"Andersson","year":"2008","journal-title":"Leuk Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T12:42:52Z","timestamp":1665751372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,10,14]]}},"alternative-id":["28278"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28278","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}